Who owns Kymera Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KYMR from SEC Form 13F filings across 277 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 277 institutions disclosed 97.0M shares of Kymera Therapeutics, Inc. worth $11.09B — about 98.8% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
277
13F holders
$11.09B
value, 2026 filers
98.8%
of shares outstanding (97.0M sh)
48
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KYMR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 12.3M | $1.42B | 0.1% | 12.6% | +5.5% |
| 2 | BAKER BROS. ADVISORS LP | 8.7M | $992.7M | 5.0% | 8.8% | 0.0% |
| 3 | Avoro Capital Advisors LLC | 7.5M | $857.1M | 7.7% | 7.6% | 0.0% |
| 4 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.1M | $815.6M | 0.1% | 7.2% | +17.4% |
| 5 | T. Rowe Price Investment Management, Inc. | 6.3M | $717.5M | 0.5% | 6.4% | +14.5% |
| 6 | BlackRock, Inc. | 5.5M | $635.1M | 0.0% | 5.6% | +9.4% |
| 7 | BVF INC/IL | 3.9M | $444.0M | 11.4% | 3.9% | -29.6% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 3.7M | $421.4M | 0.1% | 3.7% | -5.5% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.0M | $343.1M | 0.0% | 3% | +4.1% |
| 10 | Siren, L.L.C. | 2.9M | $336.7M | 6.8% | 3% | -7.9% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $336.3M | 0.0% | 3% | +1.8% |
| 12 | Atlas Venture Life Science Advisors, LLC | 2.8M | $326.5M | 37.1% | 2.9% | -37.8% |
| 13 | STATE STREET CORP | 2.7M | $313.9M | 0.0% | 2.8% | +14.5% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.8M | $208.3M | 0.0% | 1.9% | +10.4% |
| 15 | Capital Research Global Investors | 1.4M | $159.3M | 0.0% | 1.4% | -17.0% |
| 16 | GOLDMAN SACHS GROUP INC | 1.2M | $136.2M | 0.0% | 1.2% | +33.6% |
| 17 | UBS Group AG | 1.0M | $115.6M | 0.0% | 1% | -1.6% |
| 18 | ALLIANCEBERNSTEIN L.P. | 981,521 | $81.8M | 0.0% | 1% | +10.5% |
| 19 | Driehaus Capital Management LLC | 919,233 | $105.4M | 0.6% | 0.9% | -11.9% |
| 20 | Merck & Co., Inc. | 772,165 | $88.5M | 16.8% | 0.8% | 0.0% |
| 21 | NORGES BANKNEW | 757,246 | $86.8M | 0.0% | 0.8% | new |
| 22 | FEDERATED HERMES, INC. | 749,398 | $85.9M | 0.1% | 0.8% | +39.6% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 745,152 | $85.4M | 0.0% | 0.8% | +25.7% |
| 24 | FRONTIER CAPITAL MANAGEMENT CO LLC | 740,866 | $85.0M | 0.8% | 0.8% | -2.5% |
| 25 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 736,866 | $84.5M | 0.0% | 0.8% | -15.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.